Evidence map›Paper›PMID 30602391›Full record

ArticleJournal of translational medicine2019

Identification of potential miRNA-mRNA regulatory network contributing to pathogenesis of HBV-related HCC.

Weiyang Lou, Jingxing Liu, Bisha Ding, Danni Chen, Liang Xu, Jun Ding, Donghai Jiang, Lin Zhou, Shusen Zheng, Weimin Fan

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 113 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Translational cancer research · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Weiyang LouProgram of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Key Laboratory of Organ Transplantation, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China.
Jingxing LiuDepartment of Intensive Care Unit, Changxing People's Hospital of Zhejiang, Huzhou, 313100, Zhejiang Province, China.
Bisha DingProgram of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Key Laboratory of Organ Transplantation, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China.
Danni ChenProgram of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Key Laboratory of Organ Transplantation, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China.
Liang XuProgram of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Key Laboratory of Organ Transplantation, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China.
Jun DingProgram of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Key Laboratory of Organ Transplantation, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China.
Donghai JiangProgram of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Key Laboratory of Organ Transplantation, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China.
Lin ZhouProgram of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Key Laboratory of Organ Transplantation, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China.
Shusen ZhengProgram of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Key Laboratory of Organ Transplantation, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China. shusenzheng@zju.edu.cn.
Weimin FanProgram of Innovative Cancer Therapeutics, Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, College of Medicine, Key Laboratory of Organ Transplantation, Zhejiang University, 79 Qingchun Road, Hangzhou, 310003, Zhejiang Province, China. fanw@zju.edu.cn.
Zhejiang University · CNBlood Center of Zhejiang Province · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis B virus (HBV) is one of the major risk factors of hepatocellular carcinoma (HCC). Increasing evidence indicates that microRNA (miRNA)-mRNA axis is involved in HCC. However, a comprehensive miRNA-mRNA regulatory network in HBV-related HCC is still absent. This study aims to identify potential miRNA-mRNA regulatory pathways contributing to pathogenesis of HBV-related HCC.

methodsMicroarray GSE69580 was downloaded from Gene Expression Omnibus (GEO) database. GEO2R and 'R-limma' were used to conduct differential expression analysis. The common miRNAs appeared in the two analytic sets were screened as potential differentially expressed miRNAs (DE-miRNAs). The prognostic roles of screened DE-miRNAs in HCC were further evaluated using Kaplan-Meier plotter database. Target genes of DE-miRNAs were predicted by miRNet. Then, protein-protein interaction (PPI) networks were established for these targets via the STRING database, after which hub genes in the networks were identified by Cytoscape. Functional annotation and pathway enrichment analyses for the target genes were performed through DAVID database. Three enriched pathways related to HBV-related HCC were selected for further analysis and potential target genes commonly appeared in all three pathways were screened. Cytoscape was employed to construct miRNA-hub gene network. The expression and correlation of potential miRNAs and targets were further detected in clinical HBV-related HCC samples by qRT-PCR.

results7 upregulated and 9 downregulated DE-miRNAs were accessed. 5 of 7 upregulated DE-miRNAs and 5 of 7 downregulated DE-miRNAs indicated significant prognostic roles in HCC. 2312 and 1175 target genes were predicted for the upregulated and downregulated DE-miRNAs, respectively. TP53 was identified as the hub gene in the PPI networks. Pathway enrichment analysis suggested that these predicted targets were linked to hepatitis B, pathways in cancer, microRNAs in cancer and viral carcinogenesis. Further analysis of these pathways screened 20 and 16 target genes for upregulated and downregulated DE-miRNAs, respectively. By detecting the expression of 36 target genes, six candidate target genes were identified. Finally, a potential miRNA-mRNA regulatory network was established based on the results of qRT-PCR and expression correlation analysis.

conclusionsIn the study, potential miRNA-mRNA regulatory pathways were identified, exploring the underlying pathogenesis and effective therapy strategy of HBV-related HCC.

Indexed as

Gene Regulatory NetworksCarcinoma, HepatocellularCell Line, TumorDown-RegulationGene Expression ProfilingGene Expression Regulation, NeoplasticGene OntologyHepatitis B virusHumansLiver NeoplasmsMicroRNAsModels, BiologicalMolecular Sequence AnnotationProtein Interaction MapsRNA, MessengerSurvival AnalysisMicroRNAsRNA, MessengerBioinformatic analysisHepatitis B virus (HBV)Hepatocellular carcinoma (HCC)Kaplan–Meier plotter (KM-plotter)MicroRNAs (miRNAs)

Identifiers

PMID30602391
PMCPMC6317219
OpenAlexW2907605167

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.